NCT03958383 2025-04-18
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT03209869 2022-09-13
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
University of Wisconsin, Madison
Phase 1 Withdrawn
NCT00590824 2019-11-21
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
University of Wisconsin, Madison
Phase 2 Completed
NCT00109863 2019-11-19
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
University of Wisconsin, Madison
Phase 2 Completed